stockrow
Saturday 7 November 2026
Export PLRZ’s income statement to Excel — free account
Polyrizon Ltd.
PLRZ Healthcare Biotechnology
11.05
0.54
−4.66%
Follow PLRZ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (1) | (1) | (2) | (3) | — | +62.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (1) | (1) | (2) | (3) | (6) | +62.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | |||||
| Earnings | — | — | — | — | — | — | (894.54) | (494.40) | (805.20) | (4.90) | — | (82.4%) | ||||||
| Cash flow | — | — | — | — | — | — | (1,257.78) | (396.60) | (575.23) | (6.65) | 0.00 | (82.6%) | ||||||
| Capex | — | — | — | — | — | — | (3.33) | 0.00 | 0.00 | (0.01) | 0.00 | (85.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | (1,261.11) | (396.60) | (575.23) | (6.67) | 0.00 | (82.6%) | ||||||
| Book value | — | — | — | — | — | — | (1,000.00) | (141.06) | 2,650.95 | 30.86 | 0.00 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 0 | 1 | — | +811.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (1) | (1) | (1) | (5) | (8) | +58.7% | |||||
| Capex | — | — | — | — | — | — | 0 | — | — | 0 | 0 | +32.6% | ||||||
| Free cash flow | — | — | — | — | — | — | (1) | (1) | (1) | (5) | (8) | +58.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | 0 | 2 | 12 | 16 | n/m | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (3) | (12) | (16) | +602.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (1) | 0 | 5 | 21 | 24 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (121.09) | (52.57) | (24.72) | 0.00 | (24.7) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (29.79) | (45.79) | 0.00 | (45.8) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 122.64 | (63.00) | (25.38) | 0.00 | (25.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 1 | 6 | 4 | — | +100.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Polyrizon Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EDSA Edesa Biotech, Inc. | $28.8M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $28.6M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| BCTX BRIACELL THERAP | $28.6M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $28.2M | — (loss-making) | — (loss-making) | +287.18% (above 0%: growing) | n/m | +105.91% (above 0%: growing) | 100.00% | (762.98%) | Compare |
| MGX Metagenomi Therapeutics, Inc. | $27.6M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| PLRZ Polyrizon Ltd. | $27.5M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | |
| ACET Adicet Bio, Inc. | $27.3M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $26.0M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABVC ABVC BioPharma, Inc. | $25.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $27.9M | — | — | +187.48% | — | +25.83% | 100.00% | 0.00% |